IGH/MAFB Plus Translocation, Dual Fusion
The t(14;20) translocation is one of seven recurrent IGH translocations that are referred to as primary oncogenic events in around 73% of Multiple Myeloma (MM) cases1.
These translocations result in a transcription product that dysregulates further genes, such as the cyclin family of cell cycle control genes, which then disrupts normal cell division. In the case of the t(14;20) translocation, the reciprocal rearrangement brings a truncated form of the IGH μ-Enhancer (Eμ, located between the Joining (J) segments and the constant region of the IGH gene) in close contact with the MAFB gene2. The resultant fusion and the up-regulated transcription product has been shown to cause dysregulation of Cyclin D2 in around 7% of tumours3. Of the seven translocation partners of IGH in multiple myeloma (including CCND1, CCND2, CCND3, MAF, MAFA and FGFR3/MMSET), MAFB has a prevalence of around 2%4. Involvement of any of the three MAF genes provides equally poor prognoses and a similar phenotype for patients5, but the MAFB translocation shows a different prevalence in multiple myeloma patients (2%) compared to Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) cases (7%)5.
1. Avet-Loiseau et al., Blood 2002;99(6):2185-91
2. Boersma-Vreugdenhil et al., Br J Haematol 2004;126:355-63
3. Bergsagel et al., Blood 2005;106(1):296-303
4. Zhan et al., Blood 2007;109(4):1692-700
5. Chng et al., Best Pract Res Clin Haematol 2007;20:571-96
- Area of Interest*
This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.